Wall Street analysts expect Omeros Co. (NASDAQ:OMER) to post earnings of ($0.45) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.43). Omeros posted earnings of ($0.60) per share in the same quarter last year, which suggests a positive year over year growth rate of 25%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Omeros will report full year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($2.00) to ($1.19). For the next financial year, analysts expect that the business will report earnings of ($0.92) per share, with EPS estimates ranging from ($2.13) to $0.96. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Omeros.
Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million during the quarter, compared to analyst estimates of $23.18 million. Omeros’s quarterly revenue was up 1271.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.62) earnings per share.
OMER traded up $0.07 during midday trading on Friday, hitting $15.32. The stock had a trading volume of 302,520 shares, compared to its average volume of 399,532. Omeros has a 1 year low of $10.30 and a 1 year high of $27.00. The company’s fifty day moving average is $15.49. The stock has a market capitalization of $760.89 million, a P/E ratio of -6.90 and a beta of 2.98.
Hedge funds have recently made changes to their positions in the business. Chicago Equity Partners LLC bought a new position in shares of Omeros in the 2nd quarter worth $1,094,000. Swiss National Bank raised its position in shares of Omeros by 2.2% in the 2nd quarter. Swiss National Bank now owns 86,700 shares of the biopharmaceutical company’s stock worth $1,360,000 after acquiring an additional 1,900 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Omeros by 64.7% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 30,800 shares of the biopharmaceutical company’s stock worth $475,000 after acquiring an additional 12,100 shares in the last quarter. Aperio Group LLC bought a new position in shares of Omeros in the 2nd quarter worth $49,000. Finally, Mesirow Financial Investment Management Inc. raised its position in shares of Omeros by 12.0% in the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 25,092 shares of the biopharmaceutical company’s stock worth $374,000 after acquiring an additional 2,698 shares in the last quarter. Hedge funds and other institutional investors own 51.86% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: Equity Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.